ClinicalTrials.gg
Active, not recruitingNCT02694094Updated Sep 8, 2026

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

An observational study in Hypercholesterolemia, Carotid Intimal Medial Thickness 1 and Seizure, sponsored by Johns Hopkins University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Johns Hopkins University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 379 studies in Hypercholesterolemia with a site in United States — 32 open to participants now, 41 under way, 11 of them phase 3. Hypercholesterolemia · United States.

Planned enrollment
18th of 31
105 · median 260
Started
2016
with 19 others
Observational
31 of 379
4 open now
Primary completion
2026-12
later than 7 of 39 live
Registered
242nd of 379
by date

Among the 379 studies in Hypercholesterolemia with a site in United States, this one is the 18th largest by planned enrollment of the 31 observational ones that give a count, is one of 20 that started in 2016, is one of 31 observational ones, reaches primary completion later than 7 of the 39 other live ones, and was the 242nd registered.

Hypercholesterolemia

1,180 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

32 of the 379 studies in Hypercholesterolemia with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Hypercholesterolemia studies recruiting now, 25 (43%) set no upper age limit and 21 (36%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 379 studies in Hypercholesterolemia with a site in United States, or all of them as a file.
02

Study summary

This research is being done to evaluate the short term and long term effects of ketogenic diets on measures of cardiovascular health. Such measures include cholesterol levels, blood pressure, weight, and thickening of the blood vessel wall over time. Adults aged 18 or older who are already on a ketogenic diet for at least 12 months or who are interested in beginning on the modified Atkins diet may join.

Read the detailed description

If participants agree to be in this study, the investigators will ask the participants to do the following things:

At Initial enrollment for both longterm ketogenic diet and new modified Atkins diet participants

  • Review of calendars (showing seizures) and 3-day food record
  • Check height and weight, blood pressure, skin-fold thickness and waist circumference
  • Standard modified Atkins diet clinic labs will be drawn as well as levels of low density lipoprotein (LDL) fractions, fatty acids, and apolipoproteins B and A-1
  • Participant will receive a high-resolution ultrasound of the carotid arteries in the neck performed either the day of enrollment or within 1 month of enrollment

At follow-up clinic visits (month 3 and month 6) for new modified Atkins diet participants

  • Review of calendars and food records
  • Labs repeated - standard modified Atkins diet clinic labs as well as levels of low density lipoprotein (LDL) fractions, fatty acids, and apolipoproteins B and A-1
  • Check height and weight, blood pressure, skin-fold thickness and waist circumference

At follow-up clinic visits (month 12 and month 24) for new modified Atkins diet participants

  • Review of calendars and food records
  • Labs repeated - standard modified Atkins diet clinic labs as well as levels of low density lipoprotein (LDL) fractions, fatty acids, and apolipoproteins B and A-1
  • Check height and weight, blood pressure, skin-fold thickness and waist circumference
  • Participants will receive a high-resolution ultrasound of the carotid arteries in the neck performed either the day of follow-up or within 1 month of follow-up
03

Conditions studied

  • Hypercholesterolemia
  • Carotid Intimal Medial Thickness 1
  • Seizure
  • Epilepsy
  • Cardiovascular Disease
  • Cerebrovascular Disease
  • Heart Disease
  • Coronary Disease

Keywords

  • cholesterol
  • seizure
  • epilepsy
  • ketogenic
  • diet
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Study participants will be drawn from among participants in the Johns Hopkins Adult Epilepsy Diet Center and Johns Hopkins Epilepsy Center who are age 18 or older, with body mass index (BMI) > 18.5, and on a stable antiepileptic drug regimen for > 1 month.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • (BMI) > 18.5
  • Stable antiepileptic drug regimen for > 1 month.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age
  • (BMI) \< 18.5
  • Changes in antiepileptic drug regimen \< 1 month prior to participation
  • Previous cardiovascular event or treatment ((including myocardial infarction, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI))
  • Acute pancreatitis
  • Unwilling to restrict carbohydrates
  • Kidney disease
  • metabolic or mitochondrial disorder
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (estimated)
Patient registry
No
Biospecimen retention
None retained

Groups and cohorts

  • Adults on Chronic ketogenic diets

    Adults who have been on Modified Atkins or ketogenic diets for over 1 year

    Dietary Supplement: Modified Atkins or Ketogenic Diet

  • Adults naive to ketogenic diets

    Adults who have never been on Modified Atkins or ketogenic diets

Interventions

  • Dietary supplementModified Atkins or Ketogenic Diet

    Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for \> 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.

06

What researchers measure

Primary outcomes

  1. Change in carotid artery intima-media thickness (mm) measured by carotid artery ultrasound

    Carotid artery ultrasound will be used to measure the change in average intima-media thickness over time with comparisons between baseline and 12 months of diet therapy.

    Time frame: Baseline and 12 months post diet implementation

  2. Change in LDL fractions (nmol/L)

    The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 12 months of diet therapy.

    Time frame: Baseline and 12 months post diet implementation

Secondary outcomes

  1. Change in LDL fractions (nmol/L)

    The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 3 months of diet therapy.

    Time frame: Baseline and 3 months post diet implementation

  2. Change in apolipoproteins (mg/dL)

    The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 3 months of diet therapy.

    Time frame: Baseline and 3 months post diet implementation

  3. Change in apolipoproteins (mg/dL)

    The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 6 months of diet therapy.

    Time frame: Baseline and 6 months post diet implementation

  4. Change in apolipoproteins (mg/dL)

    The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 12 months of diet therapy.

    Time frame: Baseline and 12 months post diet implementation

  5. Change in apolipoproteins (mg/dL)

    The change in fasting serum levels of apolipoproteins B and A-1 will be measured over time with comparisons between baseline and 24 months of diet therapy.

    Time frame: Baseline and 24 months post diet implementation

  6. Change in LDL fractions (nmol/L)

    The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 6 months of diet therapy.

    Time frame: Baseline and 6 months post diet implementation

  7. Change in LDL fractions (nmol/L)

    The change in levels of fasting serum low density lipoprotein (LDL) fractions (nmol/L) will be measured over time with comparisons between baseline and 24 months of diet therapy.

    Time frame: Baseline and 24 months post diet implementation

  8. Change in carotid artery intima-media thickness (mm) measured by carotid artery

    Carotid artery ultrasound will be used to measure the change in average intima-media thickness over time with comparisons between baseline and 24 months of diet therapy.

    Time frame: Baseline and 24 months post diet implementation

07

Study locations

1 site
08

References and documents

Publications

  • McDonald TJW, Diaz-Arias L, Vizthum D, Henry-Barron BJ, Schlechter H, Kossoff EH, Cervenka MC. Six-month effects of modified Atkins diet implementation on indices of cardiovascular disease risk in adults with epilepsy. Nutr Neurosci. 2022 Jul;25(7):1548-1557. doi: 10.1080/1028415X.2021.1875301. Epub 2021 Jan 23. PubMed 33487129 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Dec 2026 and a completion of Mar 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Feb 29, 2016
Start
Mar 2016
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02694094
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Mar 2016
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Mackenzie C Cervenka, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion